Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on October 27, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Buyback Details - China Feihe (06186) repurchased 5.886 million shares for a total of 24.0721 million yuan, representing 0.152% of its total share capital with a year-to-date total of 13.771 million shares repurchased [1][2] - Guosheng Tang (02273) repurchased 244,400 shares for 7.1899 million yuan, with a year-to-date total of 5.5026 million shares, accounting for 2.322% of its total share capital [2] - Mengniu Dairy (02319) repurchased 400,000 shares for 5.7710 million yuan, with a year-to-date total of 21.716 million shares, representing 0.555% of its total share capital [2] Group 2: Other Notable Buybacks - Lianlian Digital (02598) repurchased 711,000 shares for 5.7458 million yuan, with a year-to-date total of 2.5925 million shares, accounting for 0.620% of its total share capital [2] - Zhongxu Future (09890) repurchased 345,200 shares for 5.0690 million yuan, with a year-to-date total of 647,400 shares, representing 1.210% of its total share capital [2] - Kangchen Pharmaceutical (01681) repurchased 100,000 shares for 1.5400 million yuan, with a year-to-date total of 740,600 shares, accounting for 8.700% of its total share capital [2][3]

Core Viewpoint - The company, Guichuang Tongqiao (02190), announced a share buyback plan, indicating confidence in its financial position and future prospects [1] Group 1 - The company will repurchase 50,000 shares at a total cost of HKD 1,197,900 [1]

Group 1 - The company, Zhichuang Tongqiao (02190), announced a share buyback plan, intending to repurchase 50,000 shares at a cost of HKD 1.1979 million [1]

Core Viewpoint - The company, Gree Chuang Tong Qiao (02190.HK), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 50,000 shares at a total cost of HKD 1.1979 million [1] - The buyback price per share ranges from HKD 23.20 to HKD 24.06 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年10月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Core Viewpoint - Multiple companies, including China Feihe and Lianyi Rong Technology, conducted share buybacks on October 24, 2025, with China Feihe leading in both the number of shares repurchased and the total amount spent [1][2]. Group 1: Buyback Details - China Feihe (06186) repurchased 5.885 million shares for a total of 23.6977 million yuan, representing 0.087% of its total share capital [2]. - Lianyi Rong Technology (09959) repurchased 2.4 million shares for 7.3782 million yuan, accounting for 3.516% of its total share capital [2]. - Beike-W (02423) repurchased 1.1784 million shares for 7 million yuan, which is 1.722% of its total share capital [2]. Group 2: Other Notable Buybacks - Yum China (09987) repurchased 17,800 shares for 6.2549 million yuan, representing 2.830% of its total share capital [2]. - Mengniu Dairy (02319) repurchased 400,000 shares for 5.7447 million yuan, which is 0.545% of its total share capital [2]. - Kangsong Pharmaceutical (01681) repurchased 100,000 shares for 1.5180 million yuan, accounting for 8.582% of its total share capital [2].

Summary of the Pharmaceutical Industry Conference Call Industry Overview - The pharmaceutical industry has entered the 2.0 phase, characterized by significant growth in the innovative drug market and a gradual move towards international markets [1][3] - High-value consumables and minimally invasive stents have begun sales in the U.S., while low-value consumables have achieved internationalization [1][3] - Surgical robots have exceeded global sales expectations, with some products like PET-CT reaching global leadership [1][4] Key Insights and Arguments - **Investment Opportunities in Innovative Drugs**: The innovative drug sector presents significant investment opportunities, with a market potential of 1.2 trillion RMB domestically and 1.8 trillion USD globally. Chinese companies are capable of entering this larger international market, particularly in ADC and bispecific antibody products [1][5] - **Advantages of Domestic Innovative Drug R&D**: Domestic R&D benefits from rich patient resources, low-cost clinical trials, and a strong pipeline reserve, with over 30% pipeline reserve in emerging fields like cell therapy and ADC [1][6] - **CRO Sector Investment Opportunities**: The CRO sector shows promising investment opportunities, with a significant increase in financing expected in 2025, particularly for clinical trials and early-stage R&D [1][7] - **CRO Performance and Future Demand**: In the first half of 2025, CRO companies performed well in overseas markets, with double-digit growth in orders. Domestic demand is expected to recover in 2026, despite weaker performance in 2025 due to project execution cycles [1][8] Additional Important Points - **Market Financing Trends**: Domestic primary market financing reached 660 million USD in August 2025, the highest monthly value in three years, with optimistic projections for the remainder of the year [1][9] - **High-Value Consumables Market Trends**: By 2026, the high-value and low-value consumables markets are expected to complete centralized procurement, with the most significant price pressure having passed. Focus areas include fast-growing surgical fields and products with high foreign investment ratios [1][12] - **Challenges and Opportunities in Medical Equipment**: The medical equipment sector faces challenges due to procurement stagnation from anti-corruption measures, but there is potential for recovery in late 2024. Companies like Mindray and new industry players are expanding into overseas markets, indicating growth potential [1][13]

Core Viewpoint - The company, Guichuang Tongqiao (02190), announced the grant of a total of 13.95 million restricted share units to selected participants on October 24, 2025 [1] Summary by Category - **Company Announcement** - Guichuang Tongqiao has issued a total of 13.95 million restricted share units to selected participants [1]

格隆汇10月24日丨归创通桥(02190.HK)公告，2025年10月24日，根据2025年股份激励计划授出1395万份 受限制股份单位。 ...

Core Viewpoint - The company, Zhichuang Tongqiao (02190), announced the grant of a total of 13.95 million restricted share units to selected participants on October 24, 2025 [1] Group 1 - The total number of restricted share units granted is 13.95 million [1] - The grant date for the restricted share units is set for October 24, 2025 [1] - The recipients of the restricted share units are selected participants [1]